SELECT * FROM `stock_list` WHERE `symbol` = "NBSE" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='NBSE' AND exchange = 'NAS' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "NBSE" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 NBSE (NeuBase Therapeutics) COGS-to-Revenue
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » COGS-to-Revenue

NeuBase Therapeutics (NeuBase Therapeutics) COGS-to-Revenue : 0.00 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics COGS-to-Revenue?

NeuBase Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

NeuBase Therapeutics's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NeuBase Therapeutics's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

NeuBase Therapeutics COGS-to-Revenue Historical Data

The historical data trend for NeuBase Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics COGS-to-Revenue Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeuBase Therapeutics COGS-to-Revenue Calculation

NeuBase Therapeutics's COGS to Revenue for the fiscal year that ended in Sep. 2021 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

NeuBase Therapeutics's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuBase Therapeutics  (NAS:NBSE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NeuBase Therapeutics's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NeuBase Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » COGS-to-Revenue
Comparable Companies
IBIO ENDV INM CYCC FWBI QLGN VRAX ADTX SCNI GBLX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
O7P:Germany O7P:Germany
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
Website
https://www.neubasetherapeutics.com
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801